The optimal level of immunosuppression in solid organtransplantation, in particular for the liver, is a delicatebalance between the benefit of preventing rejection andthe adverse side effects of immunosuppression. Thereis uncertainty about when this level is achieved in anyindividual recipient. Immunosuppression regimens varybetween individual centers and changes with time as new agents and data are available. Presently concernsabout the adverse side effects of calcineurin inhibitor,the main class of immunosuppressive agents used inliver transplantation （LT）, has led to consideration of theuse of antibody induction therapies for patients at higherrisk of developing adverse side effects. The longevityof the transplanted organ is potentially improved bybetter management of rejection episodes and specialconsideration for tailoring of immunosuppression to theindividual with viral hepatitis C, hepatocellular carcinomaor pregnancy. This review provides an overview of thecurrent strategies for post LT immunosuppression anddiscusses modifications to consider for special patientpopulations.